CA2075982A1 - Insulin compositions - Google Patents

Insulin compositions

Info

Publication number
CA2075982A1
CA2075982A1 CA002075982A CA2075982A CA2075982A1 CA 2075982 A1 CA2075982 A1 CA 2075982A1 CA 002075982 A CA002075982 A CA 002075982A CA 2075982 A CA2075982 A CA 2075982A CA 2075982 A1 CA2075982 A1 CA 2075982A1
Authority
CA
Canada
Prior art keywords
insulin
iii
ins
general formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002075982A
Other languages
English (en)
French (fr)
Inventor
Jorgen F. Hansen
Ulla Ribel-Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2075982A1 publication Critical patent/CA2075982A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
  • Medicinal Preparation (AREA)
CA002075982A 1990-02-21 1991-02-21 Insulin compositions Abandoned CA2075982A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0455/90 1990-02-21
DK045590A DK45590D0 (enEXAMPLES) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
CA2075982A1 true CA2075982A1 (en) 1991-08-22

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002075982A Abandoned CA2075982A1 (en) 1990-02-21 1991-02-21 Insulin compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (enEXAMPLES)
JP (1) JPH05503940A (enEXAMPLES)
AU (1) AU641991B2 (enEXAMPLES)
CA (1) CA2075982A1 (enEXAMPLES)
DE (1) DE69100626D1 (enEXAMPLES)
DK (1) DK45590D0 (enEXAMPLES)
HU (1) HUT63858A (enEXAMPLES)
IE (1) IE910579A1 (enEXAMPLES)
NZ (1) NZ237176A (enEXAMPLES)
PT (1) PT96841A (enEXAMPLES)
WO (1) WO1991012817A1 (enEXAMPLES)
ZA (1) ZA911279B (enEXAMPLES)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
PL178466B1 (pl) * 1993-09-17 2000-05-31 Novo Nordisk As Pochodna insuliny i kompozycja farmaceutyczna do leczenia cukrzycy
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
RU2673185C2 (ru) 2013-10-07 2018-11-22 Ново Нордиск А/С Новое производное аналога инсулина
HRP20211281T1 (hr) 2016-12-16 2021-11-12 Novo Nordisk A/S Pripravci koji sadrže inzulin
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
EP0516704B1 (en) 1993-11-10
DK45590D0 (enEXAMPLES) 1990-02-21
PT96841A (pt) 1991-11-29
AU7337891A (en) 1991-09-18
HU9202721D0 (en) 1992-12-28
IE910579A1 (en) 1991-08-28
AU641991B2 (en) 1993-10-07
HUT63858A (en) 1993-10-28
JPH05503940A (ja) 1993-06-24
EP0516704A1 (en) 1992-12-09
WO1991012817A1 (en) 1991-09-05
DE69100626D1 (de) 1993-12-16
ZA911279B (en) 1991-10-30
NZ237176A (en) 1991-12-23

Similar Documents

Publication Publication Date Title
EP0516704B1 (en) Novel insulin compositions
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
US5456922A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
DE69815877T2 (de) Aggregate von menschlichen insulinderivaten
JPH01502434A (ja) 新規インシュリン誘導体
EP0646379A1 (en) Insulin formulation
CZ85790A3 (en) Novel preparations containing associates of hyaluronic acid, and process for preparing thereof
AU2004251625A1 (en) Synthesis of high molecular weight iron-saccharidic complexes
HU227992B1 (en) Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them
ZA200600846B (en) Novel insulin derivatives
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
SA520420276B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
JPS6011426A (ja) 糖尿病患者を治療する際に有用なガラクトシル−インシユリン複合体
HUT59942A (en) Process for producing glycozylized inzulines
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
EP1308155B1 (en) Injectable solution containing a colloid of iron and shark cartilage-derived chondroitin sulfate
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
JP2716497B2 (ja) ヘモグロビン コンプレツクス
EP2026789A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
DE2646223C2 (enEXAMPLES)
CA2022513A1 (en) Formulations of phenytoin sodium for intravenous administration
EP1433482B1 (en) Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid

Legal Events

Date Code Title Description
FZDE Dead